ACTRN12613000931774已完成2 期
A Randomized, one-center, Phase 2 Study to Compare the efficacy of the treatment of patients with spontaneous pneumothorax (SP) with air leak (AL) using digital versus traditional suction drainage systems.
Department of Thoracic Surgery, General and Oncological Surgery, Medical University of Lodz0 个研究点目标入组 60 人开始时间: 2013年8月23日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- o limit 至 o limit（—）
- 性别
- All
入选标准
- •Symptomatic Spontaneous Pneumothorax
- •The treatment using chest tube drainage
- •Air leak observed after insertion of the drain into the pleura
排除标准
- •Non-Symptomatic Spontaneous Pneumothorax
- •Pneumothorax treated conservatively or using simple aspiration.
- •Chest tube drainage without air leak
研究者
相似试验
进行中（未招募）
1 期
A Phase 2 Study of Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer Subjects With Wild-Type KRAS TumorsPreviously Untreated, KRAS Wild-Type, Unresectable, Metastatic Colorectal CancerMedDRA version: 17.0Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 100000004864EUCTR2008-004281-71-DEAmgen Inc280
进行中（未招募）
1 期
A Phase 2 Study of Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer Subjects With Wild-Type KRAS TumorsEUCTR2008-004281-71-BEAmgen Inc280
进行中（未招募）
1 期
A Randomized, Multicenter, Phase 2 Study to Compare the Efficacy of Panitumumab in Combination With mFOLFOX6 to the Efficacy of Bevacizumab in Combination With mFOLFOX6 in Patients With Previously Untreated, KRAS Wild-Type, Unresectable, Metastatic Colorectal Cancer - 20070509Previously Untreated, KRAS Wild-Type, Unresectable, Metastatic Colorectal CancerMedDRA version: 9.1Level: LLTClassification code 10052362Term: Metastatic colorectal cancerEUCTR2008-004281-71-ITAmgen Inc.280
进行中（未招募）
1 期
MK-7684A (new drug co-formulation of pembrolizumab with an anti-TIGIT) plus docetaxel works to help stop or slow down the growth of your non-small cell lung cancer (NSCLC) compared to docetaxel aloneon Small Cell Lung cancerMedDRA version: 21.1Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-004034-38-DKMerck Sharp & Dohme LLC240
进行中（未招募）
1 期
MK-7684A (new drug co-formulation of pembrolizumab with an anti-TIGIT) plus docetaxel works to help stop or slow down the growth of your non-small cell lung cancer (NSCLC) compared to docetaxel aloneon Small Cell Lung cancerMedDRA version: 21.1Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-004034-38-FIMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc240